Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine in Pick's Disease/Frontotemporal Dementia
NCT00416169Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- May 2003
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
A Phase 2 trial of galantamine in frontotemporal dementia (FTD), Pick's disease, sponsored by Johnson & Johnson. Started May 2003; status: completed.
02
Drugs
galantamine
03
Conditions
frontotemporal dementia (FTD)Pick's disease
Beyond the preview
Go deeper on NCT00416169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00416169.